Fischer Imaging announced that it has completed a private placement of one million shares of its common stock to entities controlled by Deerfield Management. The shares were sold at $4 each—a 56% premium on the company’s closing stock price of
Fischer Imaging announced that it has completed a private placement of one million shares of its common stock to entities controlled by Deerfield Management. The shares were sold at $4 eacha 56% premium on the companys closing stock price of $2.56on Friday, Aug. 25.
Having been stockholders of Fischer Imaging for a number of years, we are encouraged that operationally the company has turned the corner and is ready to reap the benefits of its investment in digital mammography and other new technologies, said Arnold Snider, general partner of Deerfield.
Fischer Imagings revenue was down (SCAN 5/24/00) as it prepared an FDA submission for its SenoScan full-field digital mammography system.
This investment provides Fischer with additional financial flexibility as we prepare to launch our SenoScan full-field digital mammography system later this year, said Morgan W. Nields, chairman and CEO of Fischer.
The companys balance sheet has improved significantly over the last 12 months as Fischer completed its exit from the OEM business, said Rod Johnson, Fischers chief financial officer.
Revenue decreased 3% to $13.7 million for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of 1999. These figures do not include the sale of a $6.2-million technology license to GE Medical.
The deal with GE involves a Fischer design for a C-arm attachment for cardiology equipment. The license agreement says GE can manufacture the C-arm itself or outsource it to another company.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.